Rocket Pharmaceuticals(US:RCKT) GlobeNewswire News Roomยท2025-08-03 20:00Core Viewpoint - The Rocket Pharmaceuticals class action lawsuit alleges violations of the Securities Exchange Act of 1934, focusing on misleading information regarding the safety and clinical trial protocol of its gene therapy product RP-A501 for Danon disease [1][4]. Group 1: Lawsuit Details - The lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049, and is pending in the District of New Jersey, representing purchasers of Rocket Pharmaceuticals securities [1]. - A subsequent case, Yankov v. Rocket Pharmaceuticals, Inc., No. 25-cv-13532, has also been filed [1]. - The lawsuit claims that Rocket Pharmaceuticals provided material information about its Phase 2 trial while concealing adverse facts about the safety of RP-A501, including the risk of Serious Adverse Events [4]. Group 2: Clinical Trial Issues - On May 27, 2025, Rocket Pharmaceuticals announced that the FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a Serious Adverse Event, leading to death [5]. - The complaint states that the company failed to disclose a substantive amendment to the trial's protocol that introduced a new immunomodulatory agent, which was critical information for investors [4][5]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff [6]. - The lead plaintiff is typically the investor with the greatest financial interest and acts on behalf of all class members [6]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].